PDR-related adverse events and treatment discontinuations were more frequent with remigromig, warranting further safety evaluation Remigromig targets the Wnt pathway, offering a potential alternative ...
At Week 20, 41.4% of CSB-001-treated eyes gained at least 15 BCVA letters, compared with none of the untreated eyes Visual acuity improvements persisted for up to 16 weeks after treatment, and CSB-001 ...
ER-100 was well tolerated through Day 56 in the first 3 patients with open-angle glaucoma, with no dose-limiting toxicities, serious adverse events, or adverse events of special interest reported Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results